RT Journal Article
SR Electronic
T1 Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 – Preliminary report
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.07.21249390
DO 10.1101/2021.01.07.21249390
A1 The REMAP-CAP Investigators
A1 Anthony C. Gordon
A1 Paul R. Mouncey
A1 Farah Al-Beidh
A1 Kathryn M. Rowan
A1 Alistair D. Nichol
A1 Yaseen M. Arabi
A1 Djillali Annane
A1 Abi Beane
A1 Wilma van Bentum-Puijk
A1 Lindsay R. Berry
A1 Zahra Bhimani
A1 Marc J.M. Bonten
A1 Charlotte A. Bradbury
A1 Frank M. Brunkhorst
A1 Adrian Buzgau
A1 Allen C. Cheng
A1 Michelle A. Detry
A1 Eamon J. Duffy
A1 Lise J. Estcourt
A1 Mark Fitzgerald
A1 Herman Goossens
A1 Rashan Haniffa
A1 Alisa M. Higgins
A1 Thomas E. Hills
A1 Christopher M. Horvat
A1 Francois Lamontagne
A1 Patrick R. Lawler
A1 Helen L. Leavis
A1 Kelsey M. Linstrum
A1 Edward Litton
A1 Elizabeth Lorenzi
A1 John C. Marshall
A1 Florian B. Mayr
A1 Danny McAuley
A1 Anna McGlothlin
A1 Shay P McGuinness
A1 Bryan J. McVerry
A1 Stephanie K. Montgomery
A1 Susan C. Morpeth
A1 Srinivas Murthy
A1 Katrina Orr
A1 Rachael L. Parke
A1 Jane C. Parker
A1 Asad E. Patanwala
A1 Ville Pettilä
A1 Emma Rademaker
A1 Marlene S. Santos
A1 Christina T. Saunders
A1 Christopher W. Seymour
A1 Manu Shankar-Hari
A1 Wendy I. Sligl
A1 Alexis F. Turgeon
A1 Anne M. Turner
A1 Frank L. van de Veerdonk
A1 Ryan Zarychanski
A1 Cameron Green
A1 Roger J. Lewis
A1 Derek C. Angus
A1 Colin J. McArthur
A1 Scott Berry
A1 Steve A. Webb
A1 Lennie P.G. Derde
YR 2021
UL http://medrxiv.org/content/early/2021/01/09/2021.01.07.21249390.abstract
AB Background The efficacy of interleukin-6 receptor antagonists in critically ill patients with coronavirus disease 2019 (Covid-19) is unclear.Methods We evaluated tocilizumab and sarilumab in an ongoing international, multifactorial, adaptive platform trial. Adult patients with Covid-19, within 24 hours of commencing organ support in an intensive care unit, were randomized to receive either tocilizumab (8mg/kg) or sarilumab (400mg) or standard care (control). The primary outcome was an ordinal scale combining in-hospital mortality (assigned −1) and days free of organ support to day 21. The trial uses a Bayesian statistical model with pre-defined triggers to declare superiority, efficacy, equivalence or futility.Results Tocilizumab and sarilumab both met the pre-defined triggers for efficacy. At the time of full analysis 353 patients had been assigned to tocilizumab, 48 to sarilumab and 402 to control. Median organ support-free days were 10 (interquartile range [IQR] −1, 16), 11 (IQR 0, 16) and 0 (IQR −1, 15) for tocilizumab, sarilumab and control, respectively. Relative to control, median adjusted odds ratios were 1.64 (95% credible intervals [CrI] 1.25, 2.14) for tocilizumab and 1.76 (95%CrI 1.17, 2.91) for sarilumab, yielding >99.9% and 99.5% posterior probabilities of superiority compared with control. Hospital mortality was 28.0% (98/350) for tocilizumab, 22.2% (10/45) for sarilumab and 35.8% (142/397) for control. All secondary outcomes and analyses supported efficacy of these IL-6 receptor antagonists.Conclusions In critically ill patients with Covid-19 receiving organ support in intensive care, treatment with the IL-6 receptor antagonists, tocilizumab and sarilumab, improved outcome, including survival. (ClinicalTrials.gov number: NCT02735707)Competing Interest StatementDr. Gordon reports grants from NIHR, grants from NIHR Research Professorship (RP-2015-06-18), non-financial support from NIHR Clinical Research Network, non-financial support from Roche Products Ltd, non-financial support from Sanofi (Aventis Pharma Ltd), during the conduct of the study; personal fees from GlaxoSmithKline, personal fees from Bristol Myers Squibb, personal fees from 30 Respiratory, outside the submitted workClinical TrialNCT02735707Clinical Protocols https://www.remapcap.org/protocol-documents Funding StatementThe Platform for European Preparedness Against (Re-) emerging Epidemics (PREPARE) consortium by the European Union, FP7-HEALTH-2013-INNOVATION-1 (#602525), the Rapid European COVID-19 Emergency Research response (RECOVER) consortium by the European Unions Horizon 2020 research and innovation programme (#101003589), the Australian National Health and Medical Research Council (#APP1101719), the Health Research Council of New Zealand (#16/631), and the Canadian Institute of Health Research Strategy for Patient-Oriented Research Innovative Clinical Trials Program Grant (#158584), the UK National Institute for Health Research (NIHR) and the NIHR Imperial Biomedical Research Centre, the Health Research Board of Ireland (CTN 2014-012), the UPMC Learning While Doing Program, the Breast Cancer Research Foundation, the French Ministry of Health (PHRC-20-0147), the Minderoo Foundation and the Wellcome Trust Innovations Project (215522). ACG is funded by an NIHR Research Professorship (RP-2015-06-18) and MSH by an NIHR Clinician Scientist Fellowship (CS-2016-16-011). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health and Social Care. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Immune Modulation Domain protocol for tocilizumab and sarilumab was approved by the following independent ethics committees in these participating countries; UK, London Surrey Borders Research Ethics Committee; Netherlands, Medisch Ethische Toetsingscommissie Utrecht (METC Utrecht); Australia, Sydney Local District ethics Review Committee (Royal Prince Alfred Hospital); New Zealand, Northern A Health and Disability Ethics Committee; Ireland, St Vincents Healthcare Group Ethics and Medical Research Committee; Kingdom of Saudi Arabia, King Abdullah International Medical Research Center Institutional Review Board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be available to researchers on request subject to sponsor restrictions from 1-10-2021. Please contact info{at}remapcap.org